Channing Capital Management LLC Increases Stake in AbbVie Inc. $ABBV

Channing Capital Management LLC lifted its position in AbbVie Inc. (NYSE:ABBV) by 10.5% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 55,647 shares of the company’s stock after acquiring an additional 5,302 shares during the quarter. Channing Capital Management LLC’s holdings in AbbVie were worth $12,885,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. Bleakley Financial Group LLC lifted its position in shares of AbbVie by 4.3% in the 3rd quarter. Bleakley Financial Group LLC now owns 70,047 shares of the company’s stock worth $16,219,000 after purchasing an additional 2,897 shares during the period. Alliance Wealth Advisors LLC UT raised its stake in AbbVie by 5.8% in the third quarter. Alliance Wealth Advisors LLC UT now owns 20,463 shares of the company’s stock worth $4,738,000 after buying an additional 1,122 shares in the last quarter. Lansforsakringar Fondforvaltning AB publ lifted its holdings in AbbVie by 2.6% during the third quarter. Lansforsakringar Fondforvaltning AB publ now owns 556,498 shares of the company’s stock worth $128,852,000 after buying an additional 14,162 shares during the period. Intrust Bank NA boosted its position in AbbVie by 2.2% during the 3rd quarter. Intrust Bank NA now owns 25,437 shares of the company’s stock valued at $5,890,000 after acquiring an additional 554 shares in the last quarter. Finally, Cannon Wealth Management Services LLC purchased a new position in shares of AbbVie in the 3rd quarter valued at $214,000. 70.23% of the stock is currently owned by institutional investors.

AbbVie News Roundup

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: FDA approved the VENCLEXTA® (venetoclax) + acalabrutinib combination for previously untreated chronic lymphocytic leukemia (CLL). This is the first all‑oral, fixed‑duration combo for this setting, supported by Phase 3 AMPLIFY data—it can meaningfully expand uptake for Venclexta and acalabrutinib, strengthen AbbVie’s oncology franchise and offer a durable revenue stream versus one‑off treatments. U.S. Food and Drug Administration (FDA) Approves Combination Treatment of VENCLEXTA® (venetoclax) and Acalabrutinib for Previously Untreated Patients With Chronic Lymphocytic Leukemia (CLL)
• Positive Sentiment: Industry write‑ups frame the FDA approval as a potential new standard for a slow‑growing blood cancer, highlighting better three‑year outcomes and the “time off therapy” selling point—this can accelerate physician adoption and market share vs. chemo regimens. FDA Approval For AbbVie/AstraZeneca’s Combination Treatment Could Set New Standard For Slow Growing Blood Cancer
• Positive Sentiment: AbbVie opened a Phase 2a study for ABBV‑142 in idiopathic pulmonary fibrosis (IPF), broadening its respiratory/pulmonary pipeline beyond core immunology and oncology programs. Early‑stage pipeline depth helps investor sentiment around post‑Humira growth optionality. AbbVie Expands IPF Pipeline With New Phase 2a Study of ABBV-142
• Positive Sentiment: Board declared a $1.73 quarterly dividend (yield ~3.1%), reinforcing the income profile for dividend‑focused investors and supporting the stock’s defensive appeal. Dividend cadence and yield matter for total return expectations. AbbVie Declares Quarterly Dividend
• Neutral Sentiment: Quarterly results and commentary show Rinvoq and Skyrizi continuing to drive top‑line growth and offset Humira erosion; that underpins management’s guidance but much of these dynamics are already reflected in recent estimates. Will Immunology Drugs Continue to Drive AbbVie’s Top Line in 2026?
• Neutral Sentiment: Coverage pieces ask whether AbbVie’s post‑Humira pipeline merits renewed investor attention — useful for narrative, but these are discussion pieces rather than new data that would immediately re‑rate the stock. Should AbbVie’s (ABBV) Post-Humira Pipeline Progress Prompt a Fresh Look From Investors?
• Neutral Sentiment: Marketing/PR items (new podcast, inclusion in dividend lists, media mentions) help brand and investor awareness but are unlikely to move fundamentals in the near term. AbbVie heads to ‘The Persistence Lab’ in new podcast highlighting healthcare innovation
• Negative Sentiment: Evercore noted Tremfya’s share gains but flagged possible limits to future earnings growth and trimmed its price target slightly—this is a modest analyst headwind that could cap upside if more firms follow with tepid updates. Evercore Notes AbbVie Inc.’s (ABBV) Tremfya Gains Market Share, But Future Earnings Growth May Be Limited

AbbVie Stock Up 0.3%

Shares of AbbVie stock opened at $224.94 on Friday. The company has a 50 day moving average price of $224.04 and a 200 day moving average price of $222.06. The firm has a market capitalization of $397.56 billion, a P/E ratio of 95.31, a PEG ratio of 0.78 and a beta of 0.35. AbbVie Inc. has a 52 week low of $164.39 and a 52 week high of $244.81.

AbbVie (NYSE:ABBV) last released its earnings results on Wednesday, February 4th. The company reported $2.71 earnings per share for the quarter, topping the consensus estimate of $2.65 by $0.06. The company had revenue of $16.62 billion for the quarter, compared to the consensus estimate of $16.39 billion. AbbVie had a net margin of 6.91% and a negative return on equity of 4,184.47%. AbbVie’s revenue was up 10.0% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $2.16 EPS. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. As a group, research analysts anticipate that AbbVie Inc. will post 12.31 earnings per share for the current fiscal year.

AbbVie Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, May 15th. Investors of record on Wednesday, April 15th will be paid a $1.73 dividend. The ex-dividend date is Wednesday, April 15th. This represents a $6.92 dividend on an annualized basis and a yield of 3.1%. AbbVie’s dividend payout ratio (DPR) is 293.22%.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on ABBV shares. Sanford C. Bernstein restated a “market perform” rating on shares of AbbVie in a research note on Thursday, February 5th. Citigroup decreased their price target on shares of AbbVie from $235.00 to $230.00 and set a “neutral” rating for the company in a research report on Tuesday, January 27th. Piper Sandler lifted their price objective on shares of AbbVie from $289.00 to $299.00 and gave the stock an “overweight” rating in a research report on Wednesday. BMO Capital Markets reiterated an “outperform” rating and set a $258.00 price objective on shares of AbbVie in a research note on Thursday, January 15th. Finally, Raymond James Financial set a $256.00 target price on shares of AbbVie in a research note on Monday, November 3rd. Two research analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and nine have issued a Hold rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $252.79.

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.